Apremilast in Patients Difficult to Treat: A Multicentric Real-Life Long-Term Experience

Table 1

Characteristics of all patients reported.

Patient	Gender	Age	Type of PsO	Particular sites	PsA	Duration of disease (years)	Comorbidities	Cancer	Infection
1	F	47	VP	—	No	10	Hypertension, pathological dry eye, cluster headache, irregular alveus, and altered lipid profile with hypertriglyceridemia and heterozygous familial hypercholesterolemia	—
2	M	56	Sub-eritrodermic	—	Yes	15	Arterial hypertension, diabetes mellitus, chronic renal failure, and chronic HCV infection	—	Latent tuberculosis
3	M	71	VP	—	No		Hypercholesterolemia and obesity	NSCLC
4	F	67	VP	—	No	25	Hypertension, hypercholesterolemia, and interventricular defect with left-right shunt	Breast	—
5	M	75	PP	Palms	No	30	—	—	Latent tuberculosis
6	M	48	VP	Palms	Yes	6	COPD	—	—
7	M	58	PP	—	Yes	20	Metabolic syndrome	—	HIV
8	F	76	VP	—	No	25	—	Uterus	—

VP: vulgar psoriasis, NSCLC: non-small-cell lung carcinoma, PP: pustular psoriasis, COPD: chronic obstructive pulmonary disease, MTX: methotrexate, CyA: cyclosporine A, PsA: psoriatic arthritis, PsO: psoriasis.